相关实验视频

Updated: Sep 19, 2025

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

Published on: February 14, 2012

通过机器学习和多尺度验证,从高地大麦中获得DPP-IV抑制

Xin Bao¹, Yiyun Zhang¹, Liyang Wang²

¹National Engineering and Technology Research Center for Fruits and Vegetables, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing, 100083, PR China.

|June 3, 2025

概括

高地大麦可以通过抑制二二酶-IV (DPP-IV) 来控制血糖. 这项研究确定了具有功能性食品显著葡萄糖调节潜力的特定.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
食品科学食品科学食品科学

背景情况:

高地大麦具有调节血糖的潜力.
它可能自然含有双基化酶-IV (DPP-IV) 抑制剂.

研究的目的:

通过机器学习和虚拟查,从高地大麦蛋白中识别DPP-IV抑制.
调查已识别的的抑制机制和抗高血糖活性.

主要方法:

机器学习 (渐变增强决策树) 和用于标识的虚拟选.
在体外测试 (IC50测定),分子对接和分子动力学模拟用于机制研究.
网络药理学探索体内抗高血糖活动.

主要成果:

三种 (FPQPQ,FPRPF,YGGWN) 被确定具有不同的DPP-IV抑制功效 (IC50值:675.47,766.80,281.76μM).
FPQPQ和FPRPF作为竞争性抑制剂,而YGGWN是一种非竞争性抑制剂.
在和网络药理学分析中,发现了多目标和多途径抗高血糖效应.

结论:

已识别的高地大麦酸具有显著的DPP-IV抑制和葡萄糖调节特性.
这项研究验证了生物活性发现和机制阐明的综合方法.
研究结果支持开发基于高地大麦的功能性食品,用于糖尿病管理.

关键词:

在GBDTGBDTGBDTGBDTGBDTGBDTGBD 低血糖是一种低血糖.在 silico 预测预测分子对接是分子对接.网络药理学网络药理学

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

2 in 1: One-step Affinity Purification for the Parallel Analysis of Protein-Protein and Protein-Metabolite Complexes

Published on: August 6, 2018

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...